European Commission approves BMS’ Daklinza for Hepatitis C

Bristol-Myers Squibb (BMS) announced that the European Commission has approved Daklinza (daclatasvir), for the chronic hepatitis C virus (HCV) infection in adults


Mr Emmanuel Blin, head, worldwide commercialization, Bristol-Myers Squibb

Today's approval allows for the marketing of Daklinza in all 28 Member States of the EU, said the company's press statement.

Daklinza is a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4.

This molecule when used in combination with Sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100 percent in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors.

This product is said to be the first NS5A complex inhibitor approved in the European Union (EU) and will be available for use in combination with other medicinal products, providing a shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon and ribavirin-based regimens.

"The eradication of HCV is in sight, and with today's approval, Daklinza, in combination with other agents, will be an important option to achieve cure across many HCV genotypes and patient types for those in the EU who are in dire need of new treatment choices," said Mr Emmanuel Blin, head of worldwide commercialization, Bristol-Myers Squibb.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email